The DOI matches its Crossref record; 431 of the 431 references it cites were found in a registry or an index.
Inhibition and induction of CYP enzymes in humans: an update
Open accessAbstract
The cytochrome P450 (CYP) enzyme family is the most important enzyme system catalyzing the phase 1 metabolism of pharmaceuticals and other xenobiotics such as herbal remedies and toxic compounds in the environment. The inhibition and induction of CYPs are major mechanisms causing pharmacokinetic drug–drug interactions. This review presents a comprehensive update on the inhibitors and inducers of the specific CYP enzymes in humans. The focus is on the more recent human in vitro and in vivo findings since the publication of our previous review on this topic in 2008. In addition to the general presentation of inhibitory drugs and inducers of human CYP enzymes by drugs, herbal remedies, and toxic compounds, an in-depth view on tyrosine-kinase inhibitors and antiretroviral HIV medications as victims and perpetrators of drug–drug interactions is provided as examples of the current trends in the field. Also, a concise overview of the mechanisms of CYP induction is presented to aid the understanding of the induction phenomena.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
Lehmann, J. M., McKee, D. D., Watson, M. A., Willson, T. M., Moore, J. T., & Kliewer, S. A. (1998) · Journal of Clinical Investigation · doi:10.1172/jci3703 · Cited by 1,576
An Orphan Nuclear Receptor Activated by Pregnanes Defines a Novel Steroid Signaling Pathway
Kliewer, S. A., Moore, J. T., Wade, L., Staudinger, J. L., Watson, M. A., Jones, S. A., McKee, D. D., Oliver, B. B., Willson, T. M., Zetterström, R. H., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)80900-9 · Cited by 1,539
Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases
Cuadrado, A., Rojo, A. I., Wells, G., Hayes, J. D., Cousin, S. P., Rumsey, W. L., Attucks, O. C., Franklin, S., Levonen, A.-L., Kensler, T. W., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0008-x · Cited by 1,438
Poland, A., Glover, E., & Kende, A. S. (1976) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)33205-2 · Cited by 1,370
Metabolism and Disposition Kinetics of Nicotine
Hukkanen, J., Jacob, P., & Benowitz, N. L. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.1.3 · Cited by 1,321
Self-citationRothhammer, V., & Quintana, F. J. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0125-8 · Cited by 1,197
Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics
Schulz, M., Iwersen-Bergmann, S., Andresen, H., & Schmoldt, A. (2012) · Critical Care · doi:10.1186/cc11441 · Cited by 1,009
Molecular basis of the Keap1–Nrf2 system
Suzuki, T., & Yamamoto, M. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.06.006 · Cited by 995
Genetic contribution to variable human CYP3A-mediated metabolism
Lamba, J. K., Lin, Y. S., Schuetz, E. G., & Thummel, K. E. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00066-2 · Cited by 990
SXR, a novel steroid and xenobioticsensing nuclear receptor
Blumberg, B., Sabbagh, W., Juguilon, H., Bolado, J., van Meter, C. M., Ong, E. S., & Evans, R. M. (1998) · Genes & Development · doi:10.1101/gad.12.20.3195 · Cited by 919
The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
Greiner, B., Eichelbaum, M., Fritz, P., Kreichgauer, H.-P., von Richter, O., Zundler, J., & Kroemer, H. K. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6663 · Cited by 917
Indinavir concentrations and St John's wort
Piscitelli, S. C., Burstein, A. H., Chaitt, D., Alfaro, R. M., & Falloon, J. (2000) · The Lancet · doi:10.1016/s0140-6736(99)05712-8 · Cited by 874
Cytochrome P450 Structure, Function and Clinical Significance: A Review
Manikandan, P., & Nagini, S. (2018) · Current Drug Targets · doi:10.2174/1389450118666170125144557 · Cited by 842
Interactions Between Herbal Medicines and Prescribed Drugs: An Updated Systematic Review
Izzo, A. A., & Ernst, E. (2009) · Drugs · doi:10.2165/11317010-000000000-00000 · Cited by 801
Birdwell, K., Decker, B., Barbarino, J., Peterson, J., Stein, C., Sadee, W., Wang, D., Vinks, A., He, Y., Swen, J., et al. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.113 · Cited by 730
Drugs Behave as Substrates, Inhibitors and Inducers of Human Cytochrome P450 3A4
Zhou, S.-F. (2008) · Current Drug Metabolism · doi:10.2174/138920008784220664 · Cited by 719
Honkakoski, P., Zelko, I., Sueyoshi, T., & Negishi, M. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.10.5652 · Cited by 700
Deep learning improves prediction of drug–drug and drug–food interactions
Ryu, J. Y., Kim, H. U., & Lee, S. Y. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1803294115 · Cited by 655
Maglich, J. M., Stoltz, C. M., Goodwin, B., Hawkins-Brown, D., Moore, J. T., & Kliewer, S. A. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.3.638 · Cited by 654
St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4
Dürr, D. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.112240 · Cited by 584
van den Bent, M. J., Brandes, A. A., Rampling, R., Kouwenhoven, M. C. M., Kros, J. M., Carpentier, A. F., Clement, P. M., Frenay, M., Campone, M., Baurain, J.-F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.5984 · Cited by 575
Inhibition and induction of human cytochrome P450 enzymes: current status
Pelkonen, O., Turpeinen, M., Hakkola, J., Honkakoski, P., Hukkanen, J., & Raunio, H. (2008) · Archives of Toxicology · doi:10.1007/s00204-008-0332-8 · Cited by 569
Self-citationIdentification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes.
Kolars, J. C., Schmiedlin-Ren, P., Schuetz, J. D., Fang, C., & Watkins, P. B. (1992) · Journal of Clinical Investigation · doi:10.1172/jci116064 · Cited by 528
Baes, M., Gulick, T., Choi, H. S., Martinoli, M. G., Simha, D., & Moore, D. D. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.3.1544 · Cited by 494
Female sex and oral contraceptive use accelerate nicotine metabolism
BENOWITZ, N., LESSOVSCHLAGGAR, C., SWAN, G., & JACOBIII, P. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.01.008 · Cited by 486
Ritonavir: Clinical Pharmacokinetics and Interactions with Other Anti-HIV Agents
Hsu, A., Granneman, G. R., & Bertz, R. J. (1998) · Clinical Pharmacokinetics · doi:10.2165/00003088-199835040-00002 · Cited by 483
Fritsche, E., Schäfer, C., Calles, C., Bernsmann, T., Bernshausen, T., Wurm, M., Hübenthal, U., Cline, J. E., Hajimiragha, H., Schroeder, P., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701764104 · Cited by 437
Pratt, V. M., Scott, S. A., Pirmohamed, M., Esquivel, B., Kane, M. S., Kattman, B. L., & Malheiro, A. (2012) · Cited by 414
Hesse, L. M., Venkatakrishnan, K., Court, M. H., von Moltke, L. L., Duan, S. X., Shader, R. I., & Greenblatt, D. J. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0026-895x(24)12046-9 · Cited by 397
Revisited: Therapeutic and toxic blood concentrations of more than 1100 drugs and other xenobiotics
Schulz, M., Schmoldt, A., Andresen-Streichert, H., & Iwersen-Bergmann, S. (2020) · Critical Care · doi:10.1186/s13054-020-02915-5 · Cited by 390
The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes
Yamano, S., Tatsuno, J., & Gonzalez, F. J. (1990) · Biochemistry · doi:10.1021/bi00457a031 · Cited by 383
Thummel, K. E., Shen, D. D., Podoll, T. D., Kunze, K. L., Trager, W. F., Hartwell, P. S., Raisys, V. A., Marsh, C. L., McVicar, J. P., & Barr, D. M. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22834-8 · Cited by 355
Cloning and expression of a human Ah receptor cDNA.
Dolwick, K. M., Schmidt, J. V., Carver, L. A., Swanson, H. I., & Bradfield, C. A. (1993) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13282-3 · Cited by 348
Watkins, P. B., Murray, S. A., Winkelman, L. G., Heuman, D. M., Wrighton, S. A., & Guzelian, P. S. (1989) · Journal of Clinical Investigation · doi:10.1172/jci113933 · Cited by 345
Cytochrome P450 phenotypic ratios for predicting herb‐drug interactions in humans
Gurley, B. J., Gardner, S. F., Hubbard, M. A., Williams, D. K., Gentry, W. B., Cui, Y., & Ang, C. Y. W. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.126913 · Cited by 343
Coordinate regulation of Phase I and II xenobiotic metabolisms by the Ah receptor and Nrf2
Köhle, C., & Bock, K. W. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.01.009 · Cited by 342
McLemore, T. L., Adelberg, S., Liu, M. C., McMahon, N. A., Yu, S. J., Hubbard, W. C., Czerwinski, M., Wood, T. G., Storeng, R., Lubet, R. A., et al. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.16.1333 · Cited by 340
Resveratrol Modulates Drug- and Carcinogen-Metabolizing Enzymes in a Healthy Volunteer Study
Chow, H.-H. S., Garland, L. L., Hsu, C.-H., Vining, D. R., Chew, W. M., Miller, J. A., Perloff, M., Crowell, J. A., & Alberts, D. S. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-09-0155 · Cited by 330
11 Phytoestrogen content in foods
Mazur, W. (1998) · Baillière's Clinical Endocrinology and Metabolism · doi:10.1016/s0950-351x(98)80013-x · Cited by 329
MARSCHALL, H., WAGNER, M., ZOLLNER, G., FICKERT, P., DICZFALUSY, U., GUMHOLD, J., SILBERT, D., FUCHSBICHLER, A., BENTHIN, L., & GRUNDSTROM, R. (2005) · Gastroenterology · doi:10.1016/j.gastro.2005.05.009 · Cited by 325
Expression and Regulation of Xenobiotic-Metabolizing Cytochrome P450 (CYP) Enzymes in Human Lung
Hukkanen, J., Pelkonen, O., Hakkola, J., & Raunio, H. (2002) · Critical Reviews in Toxicology · doi:10.1080/20024091064273 · Cited by 318
Self-citationSt John's Wort: Effect on CYP3A4 activity
Roby, C. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.106793 · Cited by 316
The intralobular distribution of ethanol-inducible P450IIE1 in rat and human liver
Tsutsumi, M., Lasker, J. M., Shimizu, M., Rosman, A. S., & Lieber, C. S. (1989) · Hepatology · doi:10.1002/hep.1840100407 · Cited by 315
Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450
Diaz, D., Fabrev, I., Daujat, M., Aubert, B. S., Bories, P., Michel, H., & Maurel, P. (1990) · Gastroenterology · doi:10.1016/0016-5085(90)90963-2 · Cited by 308
The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo
Gorski, J. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.09.013 · Cited by 305
Pascussi, J., Drocourt, L., Gerbal‐Chaloin, S., Fabre, J., Maurel, P., & Vilarem, M. (2001) · European Journal of Biochemistry · doi:10.1046/j.0014-2956.2001.02540.x · Cited by 302
Assessment of CYP1A2 Activity in Clinical Practice: Why, How, and When?
Faber, M. S., Jetter, A., & Fuhr, U. (2005) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2005.pto_973160.x · Cited by 283
Grapefruit–medication interactions: Forbidden fruit or avoidable consequences?
Bailey, D. G., Dresser, G., & Arnold, J. M. O. (2013) · Canadian Medical Association Journal · doi:10.1503/cmaj.120951 · Cited by 281
Drug–drug interactions with tyrosine-kinase inhibitors: a clinical perspective
van Leeuwen, R. W. F., van Gelder, T., Mathijssen, R. H. J., & Jansman, F. G. A. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70579-5 · Cited by 279
Song, B. J., Veech, R. L., Park, S. S., Gelboin, H. V., & Gonzalez, F. J. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)94103-7 · Cited by 277
Nebert, D. W. (2017) · Progress in Lipid Research · doi:10.1016/j.plipres.2017.06.001 · Cited by 275
Niwa, T., Shiraga, T., & Takagi, A. (2005) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.28.1805 · Cited by 274
Jiang, X., Williams, K. M., Liauw, W. S., Ammit, A. J., Roufogalis, B. D., Duke, C. C., Day, R. O., & McLachlan, A. J. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2003.02051.x · Cited by 274
Preissner, S., Kroll, K., Dunkel, M., Senger, C., Goldsobel, G., Kuzman, D., Guenther, S., Winnenburg, R., Schroeder, M., & Preissner, R. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkp970 · Cited by 274
Fenner, K., Troutman, M., Kempshall, S., Cook, J., Ware, J., Smith, D., & Lee, C. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.195 · Cited by 272
Transcriptional Regulation of CYP2C9 Gene
Gerbal-Chaloin, S., Daujat, M., Pascussi, J.-M., Pichard-Garcia, L., Vilarem, M.-J., & Maurel, P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m107228200 · Cited by 262
Perucca, E., Cloyd, J. C., Critchley, D. J. P., & Fuseau, E. (2008) · Epilepsia · doi:10.1111/j.1528-1167.2008.01665.x · Cited by 260
Role of CAR and PXR in xenobiotic sensing and metabolism
Wang, Y.-M., Ong, S. S., Chai, S. C., & Chen, T. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.685237 · Cited by 246
Gurley, B. J., Gardner, S. F., Hubbard, M. A., Williams, D. K., Gentry, W. B., Cui, Y., & Ang, C. Y. W. (2005) · Drugs & Aging · doi:10.2165/00002512-200522060-00006 · Cited by 244
Resveratrol Is a Selective Human Cytochrome P450 1A1 Inhibitor
Chun, Y. J., Kim, M. Y., & Guengerich, F. P. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1152 · Cited by 243
Van Booven, D., Marsh, S., McLeod, H., Carrillo, M. W., Sangkuhl, K., Klein, T. E., & Altman, R. B. (2010) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283349e84 · Cited by 241
Antiepileptic Drugs Increase Plasma Levels of 4β-Hydroxycholesterolin Humans
Bodin, K., Bretillon, L., Aden, Y., Bertilsson, L., Broomé, U., Einarsson, C., & Diczfalusy, U. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105127200 · Cited by 241
Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions
Backman, J. T., Filppula, A. M., Niemi, M., & Neuvonen, P. J. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011411 · Cited by 240
Stimulatory effect of brussels sprouts and cabbage on human drug metabolism
Pantuck, E. J., Pantuck, C. B., Garland, W. A., Min, B. H., Wattenberg, L. W., Anderson, K. E., Kappas, A., & Conney, A. H. (1979) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt197925188 · Cited by 239
Zhou, S.-F., Yang, L.-P., Zhou, Z.-W., Liu, Y.-H., & Chan, E. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9127-y · Cited by 238
L??pez-Cort??s, L. F., Ruiz-Valderas, R., Viciana, P., Alarc??n-Gonz??lez, A., G??mez-Mateos, J., Le??n-Jimenez, E., Sarasanacenta, M., L??pez-Pua, Y., & Pach??n, J. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241090-00004 · Cited by 229
Inhibition Selectivity of Grapefruit Juice Components on Human Cytochromes P450
Tassaneeyakul, W., Guo, L.-Q., Fukuda, K., Ohta, T., & Yamazoe, Y. (2000) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.2000.1835 · Cited by 229
Takahashi, T., Lasker, J. M., Rosman, A. S., & Lieber, C. S. (1993) · Hepatology · doi:10.1002/hep.1840170213 · Cited by 228
Effect of smoking on theophylline disposition
Hunt, S. N., Jusko, W. J., & Yurchak, A. M. (1976) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1976195part1546 · Cited by 227
Rifampicin reduces effectiveness and bioavailability of prednisolone.
McAllister, W. A., Thompson, P. J., Al-Habet, S. M., & Rogers, H. J. (1983) · BMJ · doi:10.1136/bmj.286.6369.923 · Cited by 227
Pharmacogenomics of CYP2C9: Functional and Clinical Considerations
Daly, A., Rettie, A., Fowler, D., & Miners, J. (2017) · Journal of Personalized Medicine · doi:10.3390/jpm8010001 · Cited by 227
De la Torre, B. G., & Albericio, F. (2018) · Molecules · doi:10.3390/molecules23030533 · Cited by 212
Cashman, J. R., Park, S. B., Yang, Z. C., Wrighton, S. A., Jacob, P., & Benowitz, N. L. (1992) · Chemical Research in Toxicology · doi:10.1021/tx00029a008 · Cited by 211
Rosenfeld, W. E., Doose, D. R., Walker, S. A., & Nayak, R. K. (1997) · Epilepsia · doi:10.1111/j.1528-1157.1997.tb01123.x · Cited by 210
Darwish, M., Kirby, M., Robertson, P., & Hellriegel, E. T. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847010-00006 · Cited by 209
The effect of grapefruit juice on drug disposition
Hanley, M. J., Cancalon, P., Widmer, W. W., & Greenblatt, D. J. (2011) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2011.553189 · Cited by 209
Clinical Pharmacokinetics and Pharmacodynamics of Afatinib
Wind, S., Schnell, D., Ebner, T., Freiwald, M., & Stopfer, P. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0440-1 · Cited by 206
Bisphenol A and Its Analogues Activate Human Pregnane X Receptor
Sui, Y., Ai, N., Park, S.-H., Rios-Pilier, J., Perkins, J. T., Welsh, W. J., & Zhou, C. (2012) · Environmental Health Perspectives · doi:10.1289/ehp.1104426 · Cited by 205
Ferguson, S. S., Chen, Y., LeCluyse, E. L., Negishi, M., & Goldstein, J. A. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.013169 · Cited by 200
Burk, O., Koch, I., Raucy, J., Hustert, E., Eichelbaum, M., Brockmöller, J., Zanger, U. M., & Wojnowski, L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404949200 · Cited by 198
Tornio, A., Filppula, A. M., Niemi, M., & Backman, J. T. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1435 · Cited by 198
Clinical Evidence of Herbal Drugs As Perpetrators of Pharmacokinetic Drug Interactions
Hermann, R., & von Richter, O. (2012) · Planta Medica · doi:10.1055/s-0032-1315117 · Cited by 197
Yeh, R. F., Gaver, V. E., Patterson, K. B., Rezk, N. L., Baxter-Meheux, F., Blake, M. J., Eron, J. J., Klein, C. E., Rublein, J. C., & Kashuba, A. D. M. (2006) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000219774.20174.64 · Cited by 194
Oneta, C. M., Lieber, C. S., Li, J., Rüttimann, S., Schmid, B., Lattmann, J., Rosman, A. S., & Seitz, H. K. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00223-9 · Cited by 194
Ohyama, K., Nakajima, M., Suzuki, M., Shimada, N., Yamazaki, H., & Yokoi, T. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00134.x · Cited by 190
Sinha, R. R., Rothman, N., Brown, E. D., Mark, S. D., Hoover, R. N., Caporaso, N. E., Levander, O. A., Knize, M. G., Lang, N. P., & Kadlubar, F. F. (1994) · PubMed · Cited by 188
Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation
Anglicheau, D. (2003) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfg381 · Cited by 184
Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects
Hsu, A., Granneman, G. R., Witt, G., Locke, C., Denissen, J., Molla, A., Valdes, J., Smith, J., Erdman, K., Lyons, N., et al. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.5.898 · Cited by 184
Ohnhaus, E. E., & Park, B. K. (1979) · European Journal of Clinical Pharmacology · doi:10.1007/bf00609878 · Cited by 183
The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.
Crawford, P., Chadwick, D., Martin, C., Tjia, J., Back, D., & Orme, M. (1990) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1990.tb05457.x · Cited by 179
Verhoef, V. M. J., Bosgraaf, R. P., van Kemenade, F. J., Rozendaal, L., Heideman, D. A. M., Hesselink, A. T., Bekkers, R. L. M., Steenbergen, R. D. M., Massuger, L. F. A. G., Melchers, W. J. G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70019-1 · Cited by 177
Pavek, P. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00456 · Cited by 174
Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers
Ouellet*, D., Hsu, A., Qian, J., Locke, C. S., Eason, C. J., Cavanaugh, J. H., Leonard, J. M., & Granneman, G. R. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.00749.x · Cited by 173
Delfosse, V., Dendele, B., Huet, T., Grimaldi, M., Boulahtouf, A., Gerbal-Chaloin, S., Beucher, B., Roecklin, D., Muller, C., Rahmani, R., et al. (2015) · Nature Communications · doi:10.1038/ncomms9089 · Cited by 173
Effects of Cigarette Smoke on the Human Oral Mucosal Transcriptome
Boyle, J. O., Gümüş, Z. H., Kacker, A., Choksi, V. L., Bocker, J. M., Zhou, X. K., Yantiss, R. K., Hughes, D. B., Du, B., Judson, B. L., et al. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-09-0192 · Cited by 173
Xu, Y., Hashizume, T., Shuhart, M. C., Davis, C. L., Nelson, W. L., Sakaki, T., Kalhorn, T. F., Watkins, P. B., Schuetz, E. G., & Thummel, K. E. (2006) · Molecular Pharmacology · doi:10.1124/mol.105.017392 · Cited by 173
Variation in CYP2A6 Activity and Personalized Medicine
Tanner, J.-A., & Tyndale, R. (2017) · Journal of Personalized Medicine · doi:10.3390/jpm7040018 · Cited by 172
Ultraviolet-B Exposure of Human Skin Induces Cytochromes P450 1A1 and 1B1
Katiyar, S. K., Mukhtar, H., & Matsui, M. S. (2000) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2000.00876.x · Cited by 171
Cho, B. C., Kim, D.-W., Bearz, A., Laurie, S. A., McKeage, M., Borra, G., Park, K., Kim, S.-W., Ghosn, M., Ardizzoni, A., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.07.005 · Cited by 171
Effect of diphenylhydantoin on cortisol metabolism in man
Werk, E. E., MacGee, J., & Sholiton, L. J. (1964) · Journal of Clinical Investigation · doi:10.1172/jci105056 · Cited by 168
Pharmacokinetic Drug Interactions of Gefitinib with Rifampicin, Itraconazole and Metoprolol
Swaisland, H., Ranson, M., Smith, R. P., Leadbetter, J., Laight, A., McKillop, D., & Wild, M. J. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544100-00005 · Cited by 166
de la Torre, B. G., & Alberício, F. (2020) · Molecules · doi:10.3390/molecules25030745 · Cited by 165
Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects
Dutreix, C., Peng, B., Mehring, G. H., Hayes, M., Capdeville, R., Pokorny, R., & Seiberling, M. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0832-z · Cited by 164
Li, X., He, Y., Ruiz, C. H., Koenig, M., & Cameron, M. D. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.025932 · Cited by 163
Assessment of cytochrome P4502E1 induction in alcoholic patients by chlorzoxazone pharmacokinetics
Girre, C., Lucas, D., Hispard, E., Menez, C., Dally, S., & Menez, J.-F. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90524-x · Cited by 162
In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone
McCune, J. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.110215 · Cited by 162
Pharmacokinetic Drug Interaction Studies with Enzalutamide
Gibbons, J. A., de Vries, M., Krauwinkel, W. J. J., Ohtsu, Y., Noukens, J., van der Walt, J., Mol, R., Mordenti, J. J., & Ouatas, T. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0283-1 · Cited by 162
Kunze, K. L., Wienkers, L. C., Thummel, K. E., & Trager, W. F. (1996) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)07368-4 · Cited by 161
Niemelä, O., Parkkila, S., Juvonen, R. O., Viitala, K., Gelboin, H. V., & Pasanen, M. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80120-8 · Cited by 161
Bolton, A. E., Peng, B., Hubert, M., Krebs-Brown, A., Capdeville, R., Keller, U., & Seiberling, M. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0722-9 · Cited by 160
Tsai, P.-C., Glastonbury, C. A., Eliot, M. N., Bollepalli, S., Yet, I., Castillo-Fernandez, J. E., Carnero-Montoro, E., Hardiman, T., Martin, T. C., Vickers, A., et al. (2018) · Clinical Epigenetics · doi:10.1186/s13148-018-0558-0 · Cited by 160
Dolutegravir – a review of the pharmacology, efficacy, and safety in the treatment of HIV
Kandel, C., & Walmsley, S. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s84850 · Cited by 159
A Phase I Study of Indole-3-Carbinol in Women: Tolerability and Effects
Reed, G. A., Peterson, K. S., Smith, H. J., Gray, J. C., Sullivan, D. K., Mayo, M. S., Crowell, J. A., & Hurwitz, A. (2005) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0121 · Cited by 159
Human CYP2A6 Is Induced by Estrogen via Estrogen Receptor
Higashi, E., Fukami, T., Itoh, M., Kyo, S., Inoue, M., Yokoi, T., & Nakajima, M. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.016568 · Cited by 159
Ticlopidine as a Selective Mechanism-Based Inhibitor of Human Cytochrome P450 2C19
Ha-Duong, N.-T., Dijols, S., Macherey, A.-C., Goldstein, J. A., Dansette, P. M., & Mansuy, D. (2001) · Biochemistry · doi:10.1021/bi010254c · Cited by 158
O'Brien, S. G., Meinhardt, P., Bond, E., Beck, J., Peng, B., Dutreix, C., Mehring, G., Milosavljev, S., Huber, C., Capdeville, R., et al. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601152 · Cited by 158
A Review of Low-Dose Ritonavir in Protease Inhibitor Combination Therapy
Cooper, C. L., van Heeswijk, R. P. G., Gallicano, K., & Cameron, D. W. (2003) · Clinical Infectious Diseases · doi:10.1086/375233 · Cited by 158
The mechanism of the interaction between amiodarone and warfarin in humans
Heimark, L. D., Wienkers, L. C., Kunze, K. L., Gibaldi, M., Eddy, A. C., Trager, W. F., O’Reilly, R. A., & Goulart, D. A. (1992) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1992.39 · Cited by 158
Wen, X., Wang, J., Neuvonen, P. J., & Backman, J. T. (2001) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-001-0396-3 · Cited by 157
Wu, K. C., Cui, J. Y., & Klaassen, C. D. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039006 · Cited by 155
Granfors, M. T., Backman, J. T., Neuvonen, M., & Neuvonen, P. J. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.08.018 · Cited by 155
Jeong, S., Nguyen, P. D., & Desta, Z. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01123-08 · Cited by 155
Smith, G. C., Wolf, C. R., Deeni, Y., Dawe, R. S., Evans, A. T., Comrie, M., Ferguson, J., & Ibbotson, S. H. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13081-4 · Cited by 153
Inhibition and induction of cytochrome P4502E1-catalyzed oxidation by isoniazid in humans
Zand, R., Nelson, S. D., Slattery, J. T., Thummel, K. E., Kalhorn, T. F., Adams, S. P., & Wright, J. M. (1993) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1993.125 · Cited by 152
Poland, A., Smith, D. A., Kuntzman, R. G., et al. (1970) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1970115724 · Cited by 151
Insights into CYP2B6-mediated drug–drug interactions
Hedrich, W. D., Hassan, H. E., & Wang, H. (2016) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.07.016 · Cited by 151
Kawajiri, K., & Fujii‐Kuriyama, Y. (2016) · EXPERIMENTAL ANIMALS · doi:10.1538/expanim.16-0092 · Cited by 146
Wang, L., Zhou, G., Zhu, B. Y., Wu, J., Wang, J., El‐Aty, A. M. A., Li, T., Liu, J., Tian-lun, Y., Wang, D., et al. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.09.014 · Cited by 145
Chang, T. K. H., Chen, J., & Lee, W. B. K. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29205-3 · Cited by 145
Chiba, K., Kobayashi, K., Manabe, K., Tani, M., Kamataki, T., & Ishizaki, T. (1993) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38328-x · Cited by 144
Tornio, A., Filppula, A. M., Kailari, O., Neuvonen, M., Nyrönen, T., Tapaninen, T., Neuvonen, P. J., Niemi, M., & Backman, J. T. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.141 · Cited by 144
Groll, A. H., Townsend, R. W., Desai, A. V., Azie, N. E., Jones, M. E., Engelhardt, M. F., Schmitt-Hoffman, A., & Brüggemann, R. J. M. (2017) · Transplant Infectious Disease · doi:10.1111/tid.12751 · Cited by 143
Scheer, N., Ross, J., Rode, A., Zevnik, B., Sandra, N., Faust, N., & Wolf, C. R. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35483 · Cited by 142
Effect of charcoal‐broiled beef on antipyrine and theophylline metabolism
Kappas, A., Alvares, A. P., Anderson, K. E., Pantuck, E. J., Pantuck, C. B., Chang, R., & Conney, A. H. (1978) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1978234445 · Cited by 142
Reardon, D. A., Vredenburgh, J. J., Desjardins, A., Peters, K. B., Gururangan, S., Sampson, J. H., Marcello, J. E., Herndon, J. E., McLendon, R. E., Janney, D., et al. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0217-6 · Cited by 138
Fontana, R. J., Lown, K. S., Paine, M. F., Fortlage, L., Santella, R. M., Felton, J. S., Knize, M. G., Greenberg, A., & Watkins, P. B. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70554-8 · Cited by 137
Kellogg, J. J., Paine, M. F., McCune, J. S., Oberlies, N. H., & Cech, N. B. (2019) · Natural Product Reports · doi:10.1039/c8np00065d · Cited by 135
Thum, T., Erpenbeck, V. J., Moeller, J., Hohlfeld, J. M., Krug, N., & Borlak, J. T. (2006) · Environmental Health Perspectives · doi:10.1289/ehp.8861 · Cited by 134
Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine
Oscarson, M., Zanger, U. M., Rifki, O. F., KLEIN, K., Eichelbaum, M. F., & Meyer, U. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.08.013 · Cited by 134
The Cutaneous Lesions of Dioxin Exposure: Lessons from the Poisoning of Victor Yushchenko
Saurat, J. ‐., Kaya, G., Saxer‐Sekulic, N., Pardo, B., Becker, M., Fontao, L., Mottu, F., Carraux, P., Pham, X.-C., Barde, C., et al. (2011) · Toxicological Sciences · doi:10.1093/toxsci/kfr223 · Cited by 134
Willey, J. C., Coy, E. L., Frampton, M. W., Torres, A., Apostolakos, M. J., Hoehn, G., Schuermann, W. H., Thilly, W. G., Olson, D. E., Hammersley, J. R., et al. (1997) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.17.1.2783 · Cited by 133
Modulation of cytochrome P450 isozymes in human liver, by ethanol and drug intake
PERROT, N., Nalpas, B., Yang, C. S., & Beaune, P. H. (1989) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1989.tb00273.x · Cited by 127
Wang, B., & Zhou, S. F. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709789378198 · Cited by 127
Evaluation of Potential Inductive Effects of Aprepitant on Cytochrome P450 3A4 and 2C9 Activity
Shadle, C. R., Lee, Y., Majumdar, A. K., et al. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003262950 · Cited by 127
Quattrochi, L. C., & Tukey, R. H. (1993) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13403-2 · Cited by 126
The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy
Back, D. J., Bates, M., Bowden, A., Breckenridge, A., Hall, M. J., Jones, H. L., MacIver, M., Orme, M., Perucca, E., Richens, A., et al. (1980) · Contraception · doi:10.1016/0010-7824(80)90102-x · Cited by 125
Possible Interaction Between Oxcarbazepine and an Oral Contraceptive
Jensen, P. K., Saano, V., Haring, P., Svenstrup, B., & Menge, G. P. (1992) · Epilepsia · doi:10.1111/j.1528-1157.1992.tb01773.x · Cited by 125
Johnson, F. M., Agrawal, S., Burris, H. A., Rosen, L. S., Dhillon, N., Hong, D. S., Blackwood‐Chirchir, A., Luo, F. R., Sy, O., Kaul, S., et al. (2010) · Cancer · doi:10.1002/cncr.24927 · Cited by 124
Thorn, C. F., Aklillu, E., McDonagh, E. M., Klein, T. E., & Altman, R. B. (2012) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283505d5e · Cited by 124
Induction of cytochrome P450IA genes (CYP1A) by omeprazole in the human alimentary tract
McDonnell, W. M., Scheiman, J. M., & Traber, P. G. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)91171-y · Cited by 122
Zilly, W., Breimer, D. D., & Richter, E. A. (1975) · European Journal of Clinical Pharmacology · doi:10.1007/bf00614021 · Cited by 122
Kirby, B. J., Collier, A. C., Kharasch, E. D., Whittington, D., Thummel, K. E., & Unadkat, J. D. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.037523 · Cited by 121
Shi, J. G., Chen, X., Emm, T. A., Scherle, P., McGee, R. F., Lo, Y. Y. C., Landman, R. R., McKeever, E., Punwani, N. G., Williams, W. V., et al. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011405663 · Cited by 121
Signatures of Environmental Exposures Using Peripheral Leukocyte Gene Expression: Tobacco Smoke
Lampe, J. W., Stepaniants, S. B., Mao, M., Radich, J. P., Dai, H. A., Linsley, P. S., Friend, S. H., & Potter, J. D. (2004) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.445.13.3 · Cited by 120
Bock, K. W. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.06.015 · Cited by 120
Robertson, S. M. C., Davey, R. T., Voell, J., Formentini, E., Alfaro, R. M., & Penzak, S. R. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x260871 · Cited by 119
Mechanism-Based Inactivation of Cytochrome P450 3A4 by Lapatinib
Teng, W.-C., Oh, J. W., New, L. S., Wahlin, M. D., Nelson, S. D., Ho, H. K., & Chan, E. C. Y. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.065839 · Cited by 119
Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9
Simonsson, U. S. H., Jansson, B., Hai, T. N., Huong, D. X., Tybring, G., & Ashton, M. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00092-4 · Cited by 119
Townsend, R. W., Dietz, A., Hale, C., Akhtar, S., Kowalski, D. L., Lademacher, C., Lasseter, K. C., Pearlman, H., Rammelsberg, D., Schmitt‐Hoffmann, A. H., et al. (2016) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.285 · Cited by 119
Mitotane has a strong and a durable inducing effect on CYP3A4 activity
van Erp, N. P., Guchelaar, H.-J., Ploeger, B. A., Romijn, J. A., Hartigh, J. D., & Gelderblom, H. (2011) · European Journal of Endocrinology · doi:10.1530/eje-10-0956 · Cited by 118
Kuypers, D. R. J., Claes, K. J., Evenepoel, P., Maes, B., Coosemans, W., Pirenne, J., & Vanrenterghem, Y. F. C. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443110-00005 · Cited by 118
Cobicistat Versus Ritonavir: Similar Pharmacokinetic Enhancers But Some Important Differences
Tseng, A. L.-I., Hughes, C. A., Wu, J., Seet, J., & Phillips, E. J. (2017) · Annals of Pharmacotherapy · doi:10.1177/1060028017717018 · Cited by 118
Maraviroc: Pharmacokinetics and drug Interactions
Abel, S., Back, D. J., & Vourvahis, M. (2009) · Antiviral Therapy · doi:10.1177/135965350901400514 · Cited by 116
In Vitro Inhibition and Induction of Human Hepatic Cytochrome P450 Enzymes by Modafinil
Robertson, P., DeCory, H. H., Madan, A., & Parkinson, A. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15146-x · Cited by 116
Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes
Djordjević, N., Ghotbi, R., Bertilsson, L., Јаnkovic, S., & Aklillu, E. (2007) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-007-0438-6 · Cited by 115
Rifampin decreases the plasma concentrations and effects of repaglinide
Niemi, M. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.111183 · Cited by 115
Bohnert, T., Patel, A. H., Templeton, I. E., Chen, Y., Lu, C., Lai, G., Leung, L. Y., Tse, S., Einolf, H. J., Wang, Y.-H., et al. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.069096 · Cited by 115
Interaction of Sodium Warfarin and Rifampin: Studies in Man
O’Reilly, R. A. (1974) · Annals of Internal Medicine · doi:10.7326/0003-4819-81-3-337 · Cited by 114
Lucas, R. A., Gilfillan, D. J., & Bergstrom, R. F. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050527 · Cited by 114
Granfors, M. T., Backman, J. T., Laitila, J., & Neuvonen, P. J. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.009 · Cited by 113
Back, D., Tjia, J. F., Karbwang, J., & Colbert, J. E. (1988) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1988.tb03359.x · Cited by 112
Rost, K. L., & Roots, I. (1994) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1994.49 · Cited by 112
Saarikoski, S. T., Rivera, S. P., Hankinson, O., & Husgafvel‐Pursiainen, K. (2005) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.12.027 · Cited by 112
Barditch‐Crovo, P., Trapnell, C. B., Ette, E., Zacur, H. A., Coresh, J., ROCCO, L., HENDRIX, C., & Flexner, C. W. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70138-4 · Cited by 111
An Effect of o,p′-DDD on the Extra-adrenal Metabolism of Cortisol in Man
Bledsoe, T. J., Island, D. P., Ney, R. L., & Liddle, G. W. (1964) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-24-12-1303 · Cited by 111
CYP2E1 – Biochemical and Toxicological Aspects and Role in Alcohol-Induced Liver Injury
Cederbaum, A. I. (2008) · Springer eBooks · doi:10.1007/978-0-387-77300-1_6 · Cited by 110
Tran, A., Rey, E., Pons, G., Rousseau, M., d’Athis, P., Olivé, G., MATHER, G. G., Bishop, F. E., Wurden, C. J., Labroo, R. B., et al. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90044-8 · Cited by 110
Why is Research on Herbal Medicinal Products Important and How Can We Improve Its Quality?
Pelkonen, O., Xu, Q., & Fan, T.-P. (2014) · Journal of Traditional and Complementary Medicine · doi:10.4103/2225-4110.124323 · Cited by 109
Self-citationCarbamazepine but not Valproate Induces Bupropion Metabolism
Ketter, T. A., Jenkins, J. B., Schroeder, D. H., Pazzaglia, P. J., Marangell, L. B., George, M. S., Callahan, A. M., Hinton, M. L., Chao, J. Y., & Post, R. M. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199510000-00004 · Cited by 107
Effect of CYP 3A perpetrators on ibrutinib exposure in healthy participants
de Jong, J., Skee, D. M., Murphy, J., Sukbuntherng, J., Hellemans, P., Smit, J. W., de Vries, R., Jiao, J. J., Snoeys, J., & Mannaert, E. (2015) · Pharmacology Research & Perspectives · doi:10.1002/prp2.156 · Cited by 106
Induction of polymorphic 4′‐hydroxylation of S‐mephenytoin by rifampicin.
Hh, Z., Anthony, L. B., Wood, A., & Wilkinson, G. (1990) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1990.tb03799.x · Cited by 106
Smutný, T., Mani, S., & Pávek, P. (2013) · Current Drug Metabolism · doi:10.2174/1389200214666131211153307 · Cited by 106
Rao, P., Midde, N. M., Miller, D. D., Chauhan, S. C., Kumar, A., & Kumar, S. (2015) · Current Drug Metabolism · doi:10.2174/1389200216666150812123554 · Cited by 104
Jae Wook Ko, Desta, Z., Soukhova, N. V., et al. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00175.x · Cited by 103
Markowitz, J. S., Donovan, J. L., DeVane, C. L., Sipkes, L., & Chavin, K. D. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000095340.32154.c6 · Cited by 103
Niemi, M., Backman, J. T., & Neuvonen, P. J. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.05.001 · Cited by 103
Clinically relevant drug interactions with multikinase inhibitors: a review
Hussaarts, K. G. A. M., Veerman, G., Jansman, F. G. A., van Gelder, T., Mathijssen, R. H. J., & van Leeuwen, R. W. F. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918818347 · Cited by 101
Effect of phenobarbital on theophylline disposition
LANDAY, R., Gonzalez, M. A., & Taylor, J. C. (1978) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(78)90068-4 · Cited by 99
Effect of Rifampin on the Pharmacokinetics of Rosiglitazone in Healthy Subjects
Park, J. Y., Kim, K., Kang, M., et al. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.10.003 · Cited by 98
Loboz, K. K., Gross, A. S., WILLIAMS, K., Liauw, W., Day, R. O., Blievernicht, J., Zanger, U. M., & McLachlan, A. J. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.03.010 · Cited by 98
Effects of cigarette smoking and carbon monoxide on chlorzoxazone and caffeine metabolism
Benowitz, N. L., Peng, M., & Jacob, P. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.07.001 · Cited by 96
Mechanism-Based Inactivation of Human Cytochrome P4502C8 by Drugs in Vitro
Polasek, T. M., Elliot, D. J., Lewis, B. C., & Miners, J. O. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.071803 · Cited by 96
CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment
Chen, L. L., & Prasad, G. V. R. (2018) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s107710 · Cited by 96
Weber, C., Schmitt, R., Birnboeck, H., Gérard Hopfgartner, D., Eggers, H., Meyer, J., van Marle, S., Visscher, H. W., & Jonkman, J. H. G. (1999) · The Journal of Clinical Pharmacology · doi:10.1177/00912709922008344 · Cited by 95
Increase in tacrolimus trough levels after steroid withdrawal
van Duijnhoven, E. M., Boots, J. M. M., Christiaans, M. H. L., Stolk, L. M., Undre, N. A., & van Hooff, J. P. (2003) · Transplant International · doi:10.1007/s00147-003-0615-1 · Cited by 95
Jiang, X., Blair, E. Y. L., & McLachlan, A. J. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006292124 · Cited by 95
Regulation of CYP3A5 by Glucocorticoids and Cigarette Smoke in Human Lung-Derived Cells
Hukkanen, J., Väisänen, T., Lassila, A., Piipari, R., Anttila, S. L., Pelkonen, O., Raunio, H., & Hakkola, J. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.038208 · Cited by 95
Self-citationIdentification of Clinically Used Drugs That Activate Pregnane X Receptors
Shukla, S. J., Sakamuru, S., Huang, R., Moeller, T. A., Shinn, P., VanLeer, D., Auld, D. S., Austin, C. P., & Xia, M. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.035105 · Cited by 95
Sax, P. E., DeJesus, E., Crofoot, G. E., Ward, D. J., Benson, P. M., Dretler, R. H., Mills, A., Brinson, C. C., Péloquin, J., Wei, X., et al. (2017) · The Lancet HIV · doi:10.1016/s2352-3018(17)30016-4 · Cited by 95
Cited by
Cytochrome P450 Enzymes and Drug Metabolism in Humans
Zhao, M., Ma, J., Li, M., Zhang, Y., Jiang, B., Zhao, X., Huai, C., Shen, L., Zhang, N., He, L., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312808 · Cited by 1,070
Shyam Sunder, S., Sharma, U. C., & Pokharel, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01469-6 · Cited by 508
Therapeutic advances of targeting receptor tyrosine kinases in cancer
Tomuleasa, C., Tigu, A.-B., Munteanu, R., Moldovan, C.-S., Kegyes, D., Onaciu, A., Gulei, D., Ghiaur, G., Einsele, H., & Croce, C. M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01899-w · Cited by 260
Rani, J., Dhull, S. B., Rose, P. K., & Kidwai, M. K. (2024) · Phytomedicine · doi:10.1016/j.phymed.2023.155142 · Cited by 91
Psychedelic Psychiatry and the Consult-Liaison Psychiatrist: A Primer
Barnett, B. S., & Greer, G. R. (2021) · Journal of the Academy of Consultation-Liaison Psychiatry · doi:10.1016/j.jaclp.2020.12.011 · Cited by 13
Metadata
- Authors
- Hakkola, J., Hukkanen, J., Turpeinen, M., & Pelkonen, O.
- Venue
- Archives of Toxicology
- Published
- 2020-10-27
- Volume
- 94
- Issue
- 11
- Pages
- 3671-3722
- ISSN
- 0340-5761 (ISSN-L)
- 1432-0738
- OpenAlex
- W3095525985
- Cited by
- 418
- References
- 431
- FWCI
- 33.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.